Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Open-Label, Dose-escalation and Dose-Expansion Study Evaluating AO-252, a Protein-Protein Interaction Inhibitor of TACC3, in Patients With Advanced Solid Tumors With or Without Brain Metastases

NCT06136884 is registered in ClinicalTrials.gov with A2A Pharmaceuticals Inc. as lead sponsor.

NCT NCT06136884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06136884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Open-Label, Dose-escalation and Dose-Expansion Study Evaluating AO-252, a Protein-Protein Interaction Inhibitor of TACC3, in Patients With Advanced Solid Tumors With or Without Brain Metastases
Lead sponsor
A2A Pharmaceuticals Inc.
Phase
Phase 1
Overall status
Recruiting
Start date
November 2, 2023
Completion date
January 27, 2028
Enrollment
86 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

brain metastases from solid tumors, solid tumor malignancies